2012 Guidelines of the Taiwan Society of Cardiology (TSOC) for the management of ST-segment elevation myocardial infarction

Acta Cardiologica Sinica

Volumn 28, Issue 1, 2012, Pages 63-89

  Li, Yi Heng ^a   Yeh, Hung I ^b   Tsai, Chia Ti ^c   Liu, Ping Yen ^a   Lin, Tsung Hsien ^d   Wu, Tao Cheng ^e   Hung, Kuo Chun ^f   Hsieh, Yu Cheng ^g   Mar, Guang Yuan ^h   Fang, Chih Yuan ⁱ   Chiu, Kuan Ming ^j   Cheng, Jun Jack ^k   Chen, Jyh Hong ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^g TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^h KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^j FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^k SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

more..

Author keywords

Acute myocardial infarction; Guidelines

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; GLYCERYL TRINITRATE; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXYGEN; PRASUGREL; TICAGRELOR;

ANALGESIA; ANTICOAGULANT THERAPY; ANTICOAGULATION; BRADYCARDIA; CARDIOGENIC SHOCK; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL (TOPIC); CORONARY ARTERY BYPASS GRAFT; CORONARY REPERFUSION; DEFIBRILLATOR; EARLY DIAGNOSIS; ELECTROCARDIOGRAPHY; EMERGENCY CARE; FIBRINOLYTIC THERAPY; HEART FAILURE; HEART INFARCTION SIZE; HEART MUSCLE REVASCULARIZATION; HEART RUPTURE; HYPOTENSION; MEDICAL HISTORY; MITRAL VALVE REGURGITATION; OXYGEN THERAPY; PERCUTANEOUS CORONARY INTERVENTION; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TACHYCARDIA; TAIWAN; THORAX PAIN; THROMBOCYTE AGGREGATION INHIBITION;

EID: 84865496577     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. Lambert L, Brown K, Segal E, et al. Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction. JAMA 2010;303:2148-55.
2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 2004;44:671-719.
3. The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008;29: 2909-45.
4. China Society of Cardiology of Chinese Medical Association; Editorial Board of Chinese Journal of Cardiology. Guideline for diagnosis and treatment of patients with ST-elevation myocardial infarction. Zhonghua Xin Xue Guan Bing Za Zhi 2010; 38:675-90.
5. Eagle KA, Montoye CK, Riba AL, et al. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction. J Am Coll Cardiol 2005;46:1242-8.
6. Wenger NK. You've come a long way, baby: cardiovascular health and disease in women: problems and prospects. Circulation 2004;109:558-60.
7. McSweeney JC, Cody M, O'Sullivan P, et al. Women's early warning symptoms of acute myocardial infarction. Circulation 2003;108:2619-23.
8. Weaver WD, Litwin PE, Martin JS, et al. for the MITI Project Group. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991;18:657-62.
9. Spodick DH. Diagnostic electrocardiographic sequences in acute pericarditis: significance of PR segment and PR vector changes. Circulation 1973;48:575-80.
10. Menown IB, Mackenzie G, Adgey AA. Optimizing the initial 12-lead electrocardiographic diagnosis of acute myocardial infarction. Eur Heart J 2000;21:275-83.
11. Mauri F, Gasparini M, Barbonaglia L, et al. Prognostic significance of the extent of myocardial injury in acute myocardial infarction treated by streptokinase (the GISSI trial). Am J Cardiol 1989;63:1291-5.
12. Matetzky S, Freimark D, Chouraqui P, et al. Significance of ST segment elevations in posterior chest leads (V7 to V9) in patients with acute inferior myocardial infarction: application for thrombolytic therapy. J Am Coll Cardiol 1998;31:506-11.
13. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003;108:1146-62.
14. Wang K, Asinger RW, Marriott HJ. ST-segment elevation in conditions other than acute myocardial infarction. N Engl J Med 2003;349:2128-35.
15. Fibrinolytic Therapy Trialists'(FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
16. Sgarbossa EB, Pinski SL, Barbagelata A, et al. for the GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. N Engl J Med 1996;334:481-7.
17. Sgarbossa EB. Value of the ECG in suspected acute myocardial infarction with left bundle-branch block. J Electrocardiol 2000;33:87-92.
18. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
19. Maroko PR, Radvany P, Braunwald E, Hale SL. Reduction of infarct size by oxygen inhalation following acute coronary occlusion. Circulation 1975;52:360-8.
20. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
21. Come PC, Pitt B. Nitroglycerin-induced severe hypotension and bradycardia in patients with acute myocardial infarction. Circulation 1976;54:624-8.
22. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113: 2906-13.
23. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
24. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo controlled trial. Lancet 2005;366:1607-21.
25. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005;352:1179-89.
26. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA2005;294:1224-32.
27. Fang CC, Jao YT, Chen Y, et al. Glycoprotein IIb/IIIa inhibitor (tirofiban) in acute ST-segment elevation myocardial infarction. Angiology 2009;60:192-200.
28. Yip HK, Wu CJ, Chang HW, et al. Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes. Chest 2003;124:962-8.
29. Bassand J, Danchin N, Filippatos G, et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 2005;26:2733-41.
30. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003;361:13-20.
31. Tamis-Holland JE, Palazzo A, Stebbins AL, et al. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy. Am Heart J 2004;147:133-9.
32. Goldenberg I, Matetzky S, Halkin A, et al. Primary angioplasty with routine stenting compared with thrombolytic therapy in elderly patients with acute myocardial infarction. Am Heart J 2003;145:862-7.
33. Kornowski R, Mehran R, Dangas G, et al. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONSAMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2011;58:704-11.
34. Vlaar PJ, Mahmoud KD, Holmes DR Jr, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol 2011;58:692-703.
35. Rathore SS, Curtis JP, Chen J, et al. Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ 2009;338:b1807.
36. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996;348:771-5.
37. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851-6.
38. Antithrombotic Trialists' Collaboration. Collaborative metaanalysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. BMJ 2002;324:71-86.
39. Peters RG, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study. Circulation 2003;108:1682-7.
40. Cheng CI, Chen CP, Kuan PL, et al. The causes and outcomes of inadequate implementation of existing guidelines for antiplatelet treatment in patients with acute coronary syndrome: the experience from Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry). Clin Cardiol 2010;33:E40-8.
41. Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010;363:930-42.
42. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double dose versus standard-dose clopidogrel and high dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010;376:1233-43.
43. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31.
44. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: APlatelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131-41.
45. Mehilli J, Kastrati A, Schulz S, et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial Circulation 2009;119:1933-40.
46. Van't Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial Lancet 2008; 372:537-46.
47. Liu CP, Lin MS, Chiu YW, et al. Additive benefit of glycoprotein IIb/IIIa inhibition and adjunctive thrombus aspiration during primary coronary intervention: results of the Initial Thrombosuction and Tirofiban Infusion (ITTI) trial. Int J Cardiol 2012;156:174-9.
48. De Luca G, Ucci G, Cassetti E, et al. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis J Am Coll Cardiol 2009; 53:1668-73.
49. Kushner FG, Hand M, Smith Jr SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol 2009;54:2205-41.
50. Yip HK, Chang HW, Wu CJ, et al. A safe and effective regimen without heparin therapy after successful primary coronary stenting in patients with acute myocardial infarction. Jpn Heart J 2000;41:697-711.
51. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction, N Engl J Med 2006;354:1477-88.
52. Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003;42:1348-56.
53. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30.
54. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006;295:1519-30.
55. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622-32.
56. ACE-Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acutemyocardial infarction: systematic overview of individual data from 100,000 patients in randomised trials. Circulation 1998;97:2202-12.
57. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
58. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 2003;362:772-6.
59. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
60. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
61. Sevilla DC, Wagner NB, Anderson WD, et al. Sensitivity of a set of myocardial infarction screening criteria in patients with anatomically documented single and multiple infarcts. Am J Cardiol 1990;66:792-5.
62. Buja LM, Willerson JT. Infarct size: can it be measured or modified in humans? Prog Cardiovasc Dis 1987;29:271-89.
63. Hackel DB, Reimer KA, Ideker RE, et al. Comparison of enzymatic and anatomic estimates of myocardial infarction size in man. Circulation 1984;70:824-35.
64. Licka M, Zimmermann R, Zehelein J, et al. Troponin T concentrations 72 hours after myocardial infarction as a serological estimate of infarct size. Heart 2002;87:520-4.
65. Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m) Tc-sestamibi: a measure of the efficacy of therapy in acute myocardial infarction. Circulation 2000;101:101-8.
66. Ibrahim T, Nekolla SG, Hornke M, et al. Quantitative measurement of infarct size by contrast-enhanced magnetic resonance imaging early after acute myocardial infarction: Comparison with single-photon emission tomography using Tc99m-sestamibi. J Am Coll Cardiol 2005;45:544-52.
67. Friedrich MG, Abdel-Aty H, Taylor A, et al. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1581-7.
68. Hochman JS, Sleeper LA, Webb JG, et al. for the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999;341:625-34.
69. Hochman JS, Sleeper LA, White HD, et al. for the SHOCK Investigators: one-year survival following early revascularization for cardiogenic shock. JAMA 2001;285:190-2.
70. Menon V, Slater JN, White HD, et al. Acute myocardial infarction complicated by systemic hypoperfusion without hypotension: report of the SHOCK trial registry. Am J Med 2000;108:374-80.
71. Chang SN, Hwang JJ, Chen YS, et al. Clinical experience with intra-aortic balloon counterpulsation over 10 years: a retrospective cohort study of 459 patients. Resuscitation 2008;77:316-24.
72. Sheu JJ, Tsai TH, Lee FY, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction complicated with profound cardiogenic shock. Crit Care Med 2010;38:1810-7.
73. Pennington DG, Smedira NG, Samuels LE, et al. Mechanical circulatory support for acute heart failure. Ann Thorac Surg 2001; 71:S56-9.
74. Chen JM, DeRose JJ, Slater JP, et al. Improved survival rates support left ventricular assist device implantation early after myocardial infarction. J Am Coll Cardiol 1999;33:1903-8.
75. Lamas GA, Mitchell GF, Flaker GC, et al for the Survival and Ventricular Enlargement Investigators. Clinical significance of mitral regurgitation after acute myocardial infarction. Circulation 1997;96:827-33.
76. Chung SY, Lin FC, Chua S, et al. Clinical profile and outcome of first acute myocardial infarction with ischemic mitral regurgitation. Chang Gung Med J 2008;31:268-75.
77. Chua S, Hung J, Chung SY, et al. Primary percutaneous coronary intervention lowers the incidence of ischemic mitral regurgitation in patients with acute ST-elevated myocardial infarction. Circ J 2010;74:2386-92.
78. Thompson CR, Buller CE, Sleeper LA, et al. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK Trial Registry. Should we use emergently revascularize occluded coronaries in cardiogenic shock? J Am Coll Cardiol 2000;36:1104-9.
79. Byrne JG, Aranki SF, Cohn LH. Repair versus replacement of mitral valve for treating severe ischemic mitral regurgitation. Coron Artery Dis 2000;11:31-3.
80. Tepe NA, Edmunds LH. Operation for acute postinfarction mitral insufficiency and cardiogenic shock. J Thorac Cardiovasc Surg 1985;89:525-30.
81. Yip HK, Fang CY, Tsai KT, et al. The potential impact of primary percutaneous coronary intervention on ventricular septal rupture complicating acute myocardial infarction. Chest 2004;125:1622-8.
82. Crenshaw BS, Granger CB, Birnbaum Y, et al. for the GUSTO-I (Global Utilization of Streptokinase and TPAfor Occluded Coronary Arteries) Trial Investigators. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. Circulation 2000;101:27-32.
83. Menon V, Webb JG, Hillis LD, et al. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize Occluded Coronaries in cardiogenic shock? J Am Coll Cardiol 2000;36:1110-6.
84. Lemery R, Smith HC, Giuliani ER, Gersh BJ. Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention. Am J Cardiol 1992;70:147-51.
85. Skillington PD, Davies RH, Luff AJ, et al. Surgical treatment for infarct-related ventricular septal defects: improved early results combined with analysis of late functional status. J Thorac Cardiovasc Surg 1990;99:798-808.
86. Nakamura F, Minamino T, Higashino Y, et al. Cardiac free wall rupture in acute myocardial infarction: ameliorative effect of coronary reperfusion. Clin Cardiol 1992;15:244-50.
87. Pollak H, Nobis H, Mlczoch J. Frequency of left ventricular free wall rupture complicating acute myocardial infarction since the advent of thrombolysis. Am J Cardiol 1994;74:184-6.
88. Becker RC, Gore JM, Lambrew C, et al. A composite view of cardiac rupture in the United States National Registry of Myocardial Infarction. J Am Coll Cardiol 1996;27:1321-6.
89. McMullan MH, Maples MD, Kilgore TL, Hindman SH. Surgical experience with left ventricular free wall rupture. Ann Thorac Surg 2001;71:1894-8.
90. Slater J, Brown RJ, Antonelli TA, et al. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 2000;36:1117-22.
91. Chen JS, Hwang CL, Lee DY, Chen YT. Regression of left ventricular aneurysm after delayed percutaneous transluminal coronary angioplasty (PTCA) in patients with acute myocardial infarction. Int J Cardiol 1995;48:39-47.
92. Di Donato M, Sabatier M, Montiglio F, et al. Outcome of left ventricular aneurysmectomy with patch repair in patients with severely depressed pump function. Am J Cardiol 1995;76:557-61.
93. Di Donato M, Toso A, Maioli M, et al. for the RESTORE Group. Intermediate survival and predictors of death after surgical ventricular restoration. Semin Thorac Cardiovasc Surg 2001;13:468-75.
94. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the clinical application of echocardiography: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). J Am Coll Cardiol 1997;29:862-79.
95. Adler Y, Finkelstein Y, Guindo J, et al. Colchicine treatment for recurrent pericarditis: a decade of experience. Circulation 1998;97:2183-5.
96. Karagueuzian HS, Mandel WJ. Electrophysiologic mechanisms of ischemic ventricular arrhythmias: experimental and clinical correlations. Cardiac arrhythmias: their mechanisms, diagnosis, and management. 3rd ed. Philadelphia: J. B. Lippincott; 1995, p. 563-603.
97. Carmeliet E. Cardiac ionic currents and acute ischemia: from channels to arrhythmias. Physiol Rev 1999;79:917-1017.
98. Field JM, Hazinski MF, Sayre MR et al. Part 1: executive summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S640-56.
99. Neumar RW, Otto CW, Link MS, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S729-67.
100. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/ AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). J Am Coll Cardiol 2008;51:e1-62.
101. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 Guideline Update for Coronary Artery Bypass Graft Surgery: Summary Article: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004;110;1168-76.
102. Dalal HM, Zawada A, Jolly K, et al. Home based versus centre based cardiac rehabilitation: cochrane systematic review and meta-analysis. BMJ 2010;340:b5631.
103. Marchionni N, Fattirolli F, Fumagalli S, et al. Improved exercise tolerance and quality of life with cardiac rehabilitation of older patients after myocardial infarction: results of a randomized, controlled trial. Circulation 2003;107:2201-6.
104. Latini R, Maggioni AP, Flather M, et al. ACE inhibitor use in patients with myocardial infarction. Summary of evidence from clinical trials. Circulation 1995;92:3132-7.
105. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115-22.
106. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-85.
107. Chiang CE, Wang TD, Li YH, et al. 2010 Guidelines of the Taiwan Society of Cardiology for management of hypertension. J Formos Med Assoc 2010;109:740-73.
108. Bartnik M, Malmberg K, Norhammar A, et al. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J 2004;25:1990-7.
109. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
110. Wang CH, Weisel RD, Liu PP, et al. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003;107:1350-4.
111. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8.
112. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39.
113. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
114. Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-14.
115. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
116. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
117. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
118. Shyu KG, Wu CJ, Mar GY, et al. Clinical characteristics, management and in-hospital outcomes of patients with acute coronary syndrome - observations from the Taiwan ACS Full Spectrum Registry. Acta Cardiol Sin 2011;27:135-44.